• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Archives

Monthly Archive for: "March, 2021"
 Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer
0
By Nascent Biotech
In News, Science News
Posted March 31, 2021

Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

SAN DIEGO, CA / ACCESSWIRE / March 31, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech,” “Nascent,” or the “Company”), a clinical-stage [...]

READ MORE
 BioPharma Journal: Why Nascent Biotech Inc (OTCMKTS:NBIO) is Worth a Close Look
0
By Nascent Biotech
In Corporate News, News
Posted March 26, 2021

BioPharma Journal: Why Nascent Biotech Inc (OTCMKTS:NBIO) is Worth a Close Look

Nascent Biotech Inc. (OTCMKTS:NBIO) is a clinical stage biopharmaceutical company with a number of potential drivers and catalysts in play. Today, we take a look at recent analysis and [...]

READ MORE
 Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer
0
By Nascent Biotech
In News, Science News
Posted March 24, 2021

Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer

SAN DIEGO, CA / ACCESSWIRE / March 24, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier
0
By Nascent Biotech
In News
Posted March 2, 2021

Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier

SAN DIEGO, CA / ACCESSWIRE / March 2, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.